Beacon Pharmaceuticals Ltd.
Additional OffersShow all
PO: 25-50 mg at bedtime. Recommended Dose: 25 mg once daily taken orally at bedtime. Decision of dose increase has to be balanced with a higher risk o... View More
Increased or decreased bioavailabity w/ CYP1A2 (eg, fluvoxamine, ciprofloxacin), oestrogens. CYP1A2 inhibitors (eg propanolol, enoxacin). Decreased bioa... View More
Suicidal thoughts & worsening of depression. Mania, dementia, lactose intolerance. May affect ability to drive or operate machinery. Pregnancy & lactati... View More
Agomelatine possesses both melatonin receptor (MT1 and MT2) agonist and 5-hydroxytryptamine receptor (5-HT2C) antagonist properties. These properties ac... View More
Mode of Action
May be taken with or without food.
Major depressive disorder
Renal Impairment: No relevant modification in agomelatine pharmacokinetic parameters in patients with severe renal impairment has been observed.
Pregnancy Category Note
Dizziness, somnolence, insomnia, migraine, headache, nausea, diarrhoea, constipation, upper abdominal pain, hyperhidrosis, back pain, tiredness, anxiety... View More
Co-administration of potent CYP1A2 inhibitors (eg fluvoxamine or ciprofloxacin). Hepatic impairment.
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not... View More